Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis

Vadim Makarov, João Neres, Ruben C. Hartkoorn, Olga B. Ryabova, Elena Kazakova, Michal Šarkan, Stanislav Huszár, Jérémie Piton, Gaëlle S. Kolly, Anthony Vocat, Trent M. Conroy, Katarína Mikušová, Stewart T. Cole
Vadim Makarov
aMore Medicines for Tuberculosis Consortium‡
bA. N. Bakh Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
João Neres
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruben C. Hartkoorn
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga B. Ryabova
aMore Medicines for Tuberculosis Consortium‡
bA. N. Bakh Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Kazakova
aMore Medicines for Tuberculosis Consortium‡
bA. N. Bakh Institute of Biochemistry, Russian Academy of Sciences, Moscow, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michal Šarkan
aMore Medicines for Tuberculosis Consortium‡
dDepartment of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanislav Huszár
aMore Medicines for Tuberculosis Consortium‡
dDepartment of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jérémie Piton
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaëlle S. Kolly
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Vocat
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trent M. Conroy
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarína Mikušová
aMore Medicines for Tuberculosis Consortium‡
dDepartment of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Bratislava, Slovakia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stewart T. Cole
aMore Medicines for Tuberculosis Consortium‡
cGlobal Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00778-15
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

8-Nitro-benzothiazinones (BTZs), such as BTZ043 and PBTZ169, inhibit decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1) and display nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro. Structure-activity relationship (SAR) studies revealed the 8-nitro group of the BTZ scaffold to be crucial for the mechanism of action, which involves formation of a semimercaptal bond with Cys387 in the active site of DprE1. To date, substitution of the 8-nitro group has led to extensive loss of antimycobacterial activity. Here, we report the synthesis and characterization of the pyrrole-benzothiazinones PyrBTZ01 and PyrBTZ02, non-nitro-benzothiazinones that retain significant antimycobacterial activity, with MICs of 0.16 μg/ml against M. tuberculosis. These compounds inhibit DprE1 with 50% inhibitory concentration (IC50) values of <8 μM and present favorable in vitro absorption-distribution-metabolism-excretion/toxicity (ADME/T) and in vivo pharmacokinetic profiles. The most promising compound, PyrBTZ01, did not show efficacy in a mouse model of acute tuberculosis, suggesting that BTZ-mediated killing through DprE1 inhibition requires a combination of both covalent bond formation and compound potency.

INTRODUCTION

The discovery of the 8-nitro-benzothiazinone (BTZ) lead compound BTZ043 [2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4,5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one] (Fig. 1) and the identification of the enzyme decaprenylphosphoryl-β-d-ribose 2′-oxidase (DprE1) as its target provided one of the most potent agents against tuberculosis (TB) known to date (MIC of 1 ng/ml) and one of the most attractive targets for antituberculosis drug discovery, respectively (1, 2). More recently, the preclinical candidate PBTZ169 [2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one] arose from a lead optimization campaign and is currently on track to enter clinical trials (3). PBTZ169 has an MIC against Mycobacterium tuberculosis of 0.3 ng/ml.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Structures of BTZ043, PBTZ169, and PyrBTZ derivatives and their respective MICs against M. tuberculosis H37Rv.

DprE1, together with its partner enzyme DprE2, catalyzes the conversion of decaprenylphosphoryl-β-d-ribose (DPR) to its arabinose counterpart decaprenylphosphoryl-β-d-arabinose (DPA), which is the sole donor of arabinose sugars that are essential for cell wall biosynthesis in M. tuberculosis and other Corynebacterineae species (4). The drug susceptibility of DprE1 is illustrated by recent publications reporting not only covalent inhibitors such as BTZ (5–10) but also a multitude of chemical scaffolds that inhibit this target noncovalently, with some showing in vivo efficacy.

The BTZs and other reported nitroaromatic DprE1 inhibitors are suicide inhibitors of DprE1. The nitro group of these compounds is reduced specifically by DprE1 to a nitroso group, which then reacts with a key active site cysteine residue (Cys387 in M. tuberculosis) to form an irreversible covalent adduct. The nitro group of the BTZs is essential for this mechanism of inhibition, as earlier structure-activity relationship (SAR) studies demonstrated that its replacement by groups such as H, Br, CN, CF3, NH2, N,N-diacetyl, NCHN-dimethyl, NCH-phenyl, furyl, COOR, and COH led to MIC increases of >500-fold with respect to BTZ043 and greatly reduced bactericidal activity (1, 11). These substitutions were introduced because of concerns about potential mutagenicity associated with the nitro group, although the concerns have proved groundless. Here, we report the first non-nitro BTZ analogues that retain significant antimycobacterial activity through inhibition of DprE1, with a pyrrole ring replacing the nitro group.

MATERIALS AND METHODS

Chemistry.The four pyrrole-BTZs (PyrBTZs) were synthesized starting from their nitro analogues (1, 3), as described in the supplemental material.

Bacterial strains and culture conditions.All mycobacterial strains, BTZ-resistant mycobacterial mutants, and M. tuberculosis strain H37Rv were grown at 37°C, with shaking, in Middlebrook 7H9 broth (Difco) supplemented with 10% albumin-dextrose-catalase (ADC) enrichment, 0.2% glycerol, and 0.05% Tween 80. M. tuberculosis strain 18b was grown in the same medium supplemented with 50 μg/ml streptomycin.

Drug susceptibility testing.The in vitro activities against all mycobacterial strains were measured with the resazurin reduction microplate assay (REMA), by 2-fold serial dilution of the compounds in the working bacterial culture in 96-well plates (final volume of 100 μl). For M. tuberculosis and Mycobacterium bovis BCG, the plates were incubated for 1 week at 37°C; for Mycobacterium smegmatis strains, the incubation time was 24 h. Bacterial viability was determined by adding sterile resazurin (10 μl, 0.025% [wt/vol]), incubating the mixture, and measuring resazurin turnover by fluorescence (excitation wavelength, 560 nm; emission wavelength, 590 nm), using a Tecan Infinite M200 microplate reader.

DprE1 assays.The C387G and C387S mutant DprE1 proteins were generated using the pET28a-M. tuberculosis DprE1 plasmid (3) and the QuikChange site-directed mutagenesis kit (Agilent), with the primers 5′-GGCTGGAACATCGGCGTCGACTTCCCC-3′ and 3′-CCGACCTTGTAGCCGCAGCTGAAGGGG-5′ (C387G) and 5′-GGCTGGAACATCAGCGTCGACTTCCCC-3′ and 3′-CCGACCTTGTAGTCGCAGCTGAAGGGG-5′ (G387S) (mutated bases are underlined). Wild-type M. tuberculosis DprE1 and the mutant enzymes were expressed and purified as described elsewhere (3).

The 50% inhibitory concentrations (IC50s) for DprE1 were determined as described previously (12), using a coupled Amplex Red/horseradish peroxidase assay, with farnesyl-phosphoryl-β-d-ribofuranose (FPR) as the substrate. The conversion of Amplex Red to resorufin was followed by fluorescence measurements (excitation wavelength, 560 nm; emission wavelength, 590 nm) on a Tecan M200 reader, in kinetic mode, at 30°C. A negative-control sample with no inhibitor was used, and the background rate (no added FPR) was subtracted from measured rates. IC50s were determined using Prism (GraphPad Software) by fitting the inhibitor concentration (log[I]) and normalized response (V) to the equation V = 100/{10[(logIC50 − log[I])h]}, where h is the Hill coefficient for DprE1.

Decaprenylphosphoryl-β-d-ribose epimerization by M. tuberculosis H37Ra cells.Aliquots of 6 ml of M. tuberculosis H37Ra culture grown to an optical density at 600 nm (OD600) of 1.31 were harvested and washed with buffer A (50 mM MOPS [morpholinepropanesulfonic acid] [pH 7.9], 10 mM MgCl2, 5 mM 2-mercaptoethanol). The cells (∼30 mg) were incubated for 15 min on ice with 50 μl of buffer A, 16 nmol NADH, and 16 μg of PyrBTZ01 or PyrBTZ02 or 2 μg of BTZ043 in 5 μl dimethyl sulfoxide (DMSO), in a final volume of 80 μl. The reactions were started with the addition of 15,000 dpm of 5-phospho-[14C]ribose 1-diphosphate (P[14C]RPP) prepared from [14C]glucose (specific activity, 290 mCi/mmol; American Radiolabeled Chemicals, Inc.), as described elsewhere (13). After 2 h of incubation at 37°C, the reactions were stopped with 1.5 ml CHCl3/CH3OH (2:1) and subjected to a biphasic Folch wash (14). The organic phase was dried and dissolved in 40 μl of CHCl3/CH3OH/H2O/NH4OH (65:25:3.6:0.5 [vol/vol]); 25% of the sample was separated by thin-layer chromatography on silica gel plates (Merck) in CHCl3/CH3OH/NH4OH/1 M ammonium acetate/H2O (180:140:9:9:23 [vol/vol]) and visualized by autoradiography (Biomax MR-1 film; Kodak). The intensity of the bands was quantified using ImageJ software (NIH).

Molecular modeling.Docking of PyrBTZ01 and PyrBTZ02 to DprE1 was performed using the induced-fit docking module of Schrödinger-Maestro v9.1, with standard precision settings (15). The M. tuberculosis DprE1 protein structure (PDB accession no. 4NCR) was used as a template for docking. The sulfur atom of Cys387 was chosen as the centroid of the box, and the box size was generated automatically. The ligands were placed in the same pocket as PBTZ169 by superposition of the benzothiazinone core. Initial glide docking for each ligand was carried out. Side chains were trimmed automatically based on B-factors, with receptor and ligand van der Waals scaling of 0.70 and 0.50, respectively, and 20 poses were generated. Prime side chain prediction and minimization were carried out for residues within 5.0 Å of ligand poses, and side chains were optimized. This led to ligand structures and conformations that were induced to fit each pose of the receptor structure. Finally, Glide SP redocking was carried out for structures with scores within 30.0 kcal/mol of the best structure and within the top 9 structures overall.

Cytotoxicity studies.The cytotoxicity of the compounds was measured as described previously (8), against two human hepatic cell lines (HepG2 and Huh7), a human lung epithelial cell line (A549), and a human monocytic cell line (THP-1). Briefly, cells were incubated (4,000 cells/well) with serial dilutions of compounds (2-fold dilutions; 100 to 0.1 μg/ml) in a 96-well microplate. Following incubation for 3 days at 37°C, cell viability was determined by adding resazurin for 4 h at 37°C and measuring the fluorescence of the resorufin metabolite (excitation wavelength, 560 nm; emission wavelength, 590 nm) using a Tecan Infinite M200 microplate reader. Data were corrected for background (no-cell control) and expressed as a percentage of the value for untreated cells (cells only).

Metabolic stability in vitro.The intrinsic clearance (CLint) of compounds was determined using both mouse and human liver microsomes. Briefly, 100 μg of mouse (CD-1) or human liver microsomes (both from Invitrogen) were mixed in 0.1 M phosphate buffer (pH 7.4) containing 1 μl of compound dissolved in DMSO at 100 μg/ml, in a final volume of 50 μl. In parallel, an NADPH-regenerating system (Promega) was prepared in 0.1 M phosphate buffer (pH 7.4). The solutions were preincubated at 37°C for 10 min before the intrinsic clearance assessment was initiated by mixing the two solutions (50 μl of each; final compound concentration, 1 μg/ml) at 37°C. After 0, 5, 10, 15, 30, and 60 min, the reactions were terminated by transferring 100 μl of the reaction mixture into 100 μl of acetonitrile and placing the mixture on ice for 30 min, for full protein precipitation. Samples were then centrifuged at 12,000 × g for 10 min, and the supernatant was injected onto a high-performance liquid chromatography (HPLC) column (Dionex) to quantify the amount of parent compound remaining over time. Carbamazepine (1 μg/ml) was used as a control for low intrinsic clearance.

Pharmacokinetic studies in mice.PyrBTZ01 (50 mg/kg) was administered by gavage as a solution (5 mg/ml) in 0.5% carboxymethyl cellulose (CMC) in water, using three BALB/c mice per time point. At each time point (0, 15, 30, 60, 120, 240, and 480 min), mice were sacrificed by cardiac puncture and blood was collected. Plasma was separated by centrifugation for 10 min at 2,200 × g at 4°C and was flash frozen in liquid nitrogen for storage at −80°C for subsequent mass spectrometric (MS) analysis. Quantification was performed using an external calibration curve of PyrBTZ01 at different concentrations in mouse serum. Ultraperformance liquid chromatography (UPLC) separation was performed with an Agilent 1290 Infinity liquid chromatography (LC) system, including a 1290 Infinity LC system binary pump with an integrated degasser, a high-performance autosampler, and a thermostatted column compartment. Samples (2 μl) were injected onto a Zorbax Extend-C18 analytical column (2.1 by 50 mm; particle size, 1.8 μm; Agilent Technologies) operated at 40°C, using H2O/0.1% HCOOH as mobile phase A and CH3CN/0.1% HCOOH as mobile phase B, with a gradient of 2 to 100% mobile phase B in 5 min, at a flow rate of 0.4 ml/min. All samples were analyzed in duplicate. The UPLC system was interfaced with a 6530 accurate-mass quadrupole-time of flight (Q-TOF) LC/MS system (Agilent Technologies). Electrospray ionization MS data were acquired in the positive ionization mode in the mass range of m/z 100 to 1,000, at a rate of 2 spectra/s. Experimental parameters were set as follows: fragmentor voltage, 190 V; capillary voltage, 3,500 V; gas temperature, 300°C; sheath gas temperature, 350°C. External calibration of the instrument was carried out with ESI-L solution (Agilent). Data were processed using MassHunter quantitative analysis compliance software. Extracted ion chromatograms (EICs) of ions at m/z 432.0835 (eluted at 4.24 min) were integrated, and quantification was performed using the external calibration curve for PyrBTZ01 in mouse serum.

Efficacy studies in vivo.Male BALB/c mice (age, 5 to 6 weeks; Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow, Russia) were infected through intravenous injection of 5 × 106 CFU of M. tuberculosis H37Rv in the lateral tail vein (10 mice per study group). Treatment began on day 8 after infection, and PyrBTZ01 (50 mg/kg) or isoniazid (25 mg/kg) was administered by gavage 5 days/week for 4 weeks. A group of untreated mice was used as a control group. The mice were euthanized, lungs were excised and homogenized, and dilutions were plated on Dubos agar. When the mice died before the end of the experiment, lung CFU counts were performed immediately. Plates were incubated for 24 days at 37°C, and the number of CFU in the lungs was determined. Experiments were approved by the State Veterinary Service of the Russian Federation (authorization no. 250 0219882).

RESULTS

Pyrrole-BTZ analogues are potent antimycobacterial agents.Following our discovery of BTZ043, we performed extensive SAR studies of this scaffold. Significant modifications were tolerated at position 2 of the BTZ ring system, and this led to the development of the preclinical candidate PBTZ169 from the lead compound BTZ043 (3). We also explored several functional groups as replacements for the 8-nitro group, which invariably led to greatly reduced antimycobacterial activity, i.e., 500- to 5,000-fold increases in MICs (1, 2). An interesting exception was the 8-pyrrole substitution (yielding PyrBTZ compounds) (Fig. 1), which was introduced into the BTZ or PyrBTZ scaffold by using the respective nitro-BTZs as starting materials, as shown in Fig. 2.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Synthetic routes for the synthesis of pyrrole-BTZs. Step a, NaHS, NH4Cl, ethanol; step b, (i) 2,5-dimethoxytetrahydrofuran, acetic acid, reflux; (ii) NaOH; step c, 2,5-hexanedione, p-toluenesulfonic acid, toluene, reflux.

Compounds PyrBTZ01 [2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4,5]dec-8-yl]-8-(1H-pyrrol-1-yl)-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one] and PyrBTZ02 [2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-(1H-pyrrol-1-yl)-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one], the pyrrole analogues of BTZ043 and PBTZ169, respectively, both displayed MICs of 0.16 μg/ml against M. tuberculosis H37Rv. PyrBTZ03 [2-(4-butylpiperazin-1-yl)-8-(1H-pyrrol-1-yl)-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one], a PyrBTZ analogue bearing a n-butyl chain on the piperazine ring, presented a higher MIC of 0.62 μg/ml (Fig. 1). Previous literature reports described the oxidation of pyrroles, particularly dimethyl-substituted pyrroles, in the presence of nucleophiles (16). Therefore, we synthesized PyrBTZ04 [2-[4-(cyclohexylmethyl)piperazin-1-yl]-8-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one], a dimethylpyrrole analogue of PBTZ169, to evaluate whether this group could be oxidized by flavin-containing DprE1 and whether the resulting product could form a covalent adduct with Cys387, making this compound an irreversible inhibitor of the enzyme. However, because the MIC of PyrBTZ04 (2.5 μg/ml) was significantly higher than those observed for the unsubstituted pyrrole compounds PyrBTZ01, PyrBTZ02, and PyrBTZ03 (Fig. 1), PyrBTZ04 was not explored further.

PyrBTZs kill M. tuberculosis through inhibition of DprE1.The two most potent PyrBTZ analogues, PyrBTZ01 and PyrBTZ02, were characterized in depth to confirm their mechanisms of action. Because the PyrBTZs were expected to target DprE1, we first determined their MICs against various mycobacterial strains (Table 1) that were fully susceptible or resistant to BTZ due to mutations in the key active site Cys residue (Cys387 in M. tuberculosis and M. bovis and Cys394 in M. smegmatis). Both compounds displayed >600-fold increases in MICs against the BTZ-resistant strains versus wild-type M. tuberculosis, thus confirming DprE1 as their target. Similar results were obtained with matched BTZ-susceptible strains and resistant mutants of M. bovis BCG and M. smegmatis (Table 1). Like other BTZ derivatives, and cell wall inhibitors generally, PyrBTZ01 and PyrBTZ02 were inactive against the streptomycin-starved 18b strain (ss18b), a model for nonreplicating M. tuberculosis (17).

View this table:
  • View inline
  • View popup
TABLE 1

MIC99 values for PyrBTZ01 and PyrBTZ02 against wild-type and BTZ-resistant mycobacterial strains

Genetic analysis.To assess whether additional mutations in the essential flavoenzyme DprE1 could cause resistance to PyrBTZs, we generated PyrBTZ01-resistant mutants of M. tuberculosis. The mutants arose at a frequency of 10−8 and displayed MICs of >100 μg/ml for both PyrBTZ01 and PyrBTZ02. Surprisingly, Sanger sequencing of the dprE1 gene in four distinct mutants revealed single nucleotide changes in the Cys387 codon, which translated to a Cys→Ser mutation, as seen in the BTZ043-resistant NTB1 strain (Table 1) (1).

The cross-resistance to the PyrBTZs displayed by the NTB1 strain and the newly generated PyrBTZ01-resistant mutants, due to the Cys387Ser mutation, was unexpected, since Cys387 is required for the binding of covalent nitroaromatic inhibitors, including nitro-BTZs, but not noncovalent inhibitors (18). The PyrBTZs with nonsubstituted pyrroles were not expected to form covalent adducts with Cys387. To investigate this, we incubated M. tuberculosis DprE1 with its substrate farnesyl-phospho-ribose in the presence of PyrBTZ01 or PyrBTZ02, followed by mass spectrometric analysis, as described previously (3). In contrast to the situation observed for BTZ043 or PBTZ169, for which covalent adducts with DprE1 were clearly identified (3, 19), no covalent adducts were observed following incubation with PyrBTZ01 or PyrBTZ02.

Enzymatic analysis.PyrBTZ01 and PyrBTZ02 were then tested in the Amplex Red peroxidase-coupled enzymatic assay with recombinant wild-type M. tuberculosis DprE1 and were found to inhibit the enzyme with IC50 values of 1.61 μM (PyrBTZ01) and 7.34 μM (PyrBTZ02) (Table 2). The IC50 values were higher than expected based on the relatively low MICs in M. tuberculosis and in comparison with values reported elsewhere for other noncovalent inhibitors such as the best aminoquinolones (IC50 of 0.02 μM and MIC of 0.39 μM) (20) and pyrazolopyridones (IC50 of 0.01 μM and MIC of 0.1 μM) (21). The favorable MICs observed for the PyrBTZs could be indicative of better uptake, easier access to DprE1, and accumulation in the bacterium, or even a secondary target in M. tuberculosis. The inhibition of BTZ-resistant DprE1 followed the trend observed in the MIC measurements, with the C387G mutant being more resistant to inhibition by PyrBTZ01, PyrBTZ02, and BTZ043 (∼7- to 9-fold increases in IC50) than the C387S mutant (∼2.5- to 4-fold increases in IC50).

View this table:
  • View inline
  • View popup
TABLE 2

IC50 values measured for PyrBTZ01, PyrBTZ02, and BTZ043 against wild-type and BTZ-resistant M. tuberculosis DprE1

Much lower sensitivity of the DprE1 enzyme to PyrBTZ01 and PyrBTZ02, compared to BTZ043, was confirmed in a radioactive assay that monitored the incorporation of P[14C]RPP into [14C]DPA and its precursors by M. tuberculosis H37Ra cells. We observed partial inhibition of DPA synthesis when 200 μg/ml PyrBTZ01 and PyrBTZ02 were added (Fig. 3), whereas complete inhibition was obtained in the presence of only 25 μg/ml BTZ043.

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Comparative inhibition of DPA synthesis. Decaprenylphosphoryl-β-d-ribose epimerization by M. tuberculosis H37Ra cells was inhibited by PyrBTZ01 (200 μg/ml), PyrBTZ02 (200 μg/ml), and BTZ043 (25 μg/ml). The ratios of the intensities of the DPA and DPR bands (quantified in ImageJ) are also shown.

Structural studies of PyrBTZ binding to DprE1.To understand the mode of binding of PyrBTZ01 and PyrBTZ02 to DprE1 and the intriguing role of Cys387, we have performed extensive cocrystallization studies of these compounds with DprE1 from M. tuberculosis and M. smegmatis, but no PyrBTZ has been found in the crystals to date. Previous reports described the formation of aromatic-thiol hydrogen bonds in proteins, involving cysteine residues (22, 23); in theory, this could explain the role of Cys387 in binding PyrBTZ compounds. To test this hypothesis, we modeled PyrBTZ01 and PyrBTZ02 in the active site of M. tuberculosis DprE1, using the cocrystal structure containing PBTZ169 (PDB accession no. 4NCR) that was disclosed recently (3). The modeling work assessed the possibility that the active site of DprE1 could accommodate PyrBTZ01 or PyrBTZ02 by placing the pyrrole rings in the vicinity of Cys387 and maintaining the overall binding mode of the BTZ ring system that was observed for BTZ043 and PBTZ169 (3, 19). Results of the induced-fit docking studies produced similar poses for both pyrrole derivatives, but these were slightly shifted in comparison with the positions of BTZ043 and PBTZ169 (Fig. 4A and B). Indeed, the pyrrole ring is placed just below Cys387, leading to PyrBTZ01 and PyrBTZ02 being less embedded (Fig. 4C and D). Conformational changes in a few neighboring residues (for example, Lys418 or Trp230) would be required to stabilize the pyrrole compounds in the pocket in the same manner as PBTZ169 in the crystal structure of DprE1 (3).

FIG 4
  • Open in new tab
  • Download powerpoint
FIG 4

Molecular docking of pyrrole-BTZs in the DprE1 active site. Superposition of the M. tuberculosis DprE1 crystal structure with BTZ043 (A) or PBTZ169 (B) and the modeled structures of docked PyrBTZ01 (blue carbons) (C) and docked PyrBTZ02 (red carbons) (D) show an induced-fit complex. Cocrystallized DprE1 with PBTZ169 (PDB accession no. 4NCR) (yellow carbons) was used as the template. Residues important for the interactions are shown as sticks. FAD, flavin adenine dinucleotide.

PyrBTZs and BTZ043 present similar absorption-distribution-metabolism-excretion/toxicity (ADME/T) profiles.PyrBTZ01 and PyrBTZ02 were tested in parallel with BTZ043 for their cytotoxicity (50% toxic dose [TD50]) against four human cell lines, namely, liver carcinoma HepG2, hepatoma Huh7, lung epithelial A549, and monocytic THP-1 cell lines (Table 3). Both compounds were less cytotoxic than BTZ043, with PyrBTZ02 being the least cytotoxic. BTZ043 presented the highest selectivity index (SI) due to its extremely low MIC, followed by PyrBTZ02 and PyrBTZ01 (Table 3). As reported previously for BTZ043 and PBTZ169 (1, 3), neither PyrBTZ01 nor PyrBTZ02 was mutagenic when tested in the SOS chromotest (24).

View this table:
  • View inline
  • View popup
TABLE 3

Cytotoxicity (TD50) and selectivity index values

Next, we evaluated, using both mouse and human liver microsomes, the in vitro metabolic stabilities (intrinsic clearance [CLint]) of PyrBTZ01 and PyrBTZ02 in parallel with BTZ043, PBTZ169, and carbamazepine (a control compound for low CLint). PyrBTZ01 and PyrBTZ02 presented intermediate CLint values in the presence of mouse and human microsomes (Table 4), and these values were similar to those observed for BTZ043 and PBTZ169, thus suggesting reasonable compound exposure in mice.

View this table:
  • View inline
  • View popup
TABLE 4

Metabolic stability of PyrBTZ01 and PyrBTZ02 in the presence of mouse and human microsomes

To confirm this, we performed an in vivo pharmacokinetic (PK) study of PyrBTZ01 in BALB/c mice, following oral administration of a single 50-mg/kg dose. Comparison of the PK profiles of PyrBTZ01 and its analogue BTZ043 at a dose of 25 mg/kg (Fig. 4) showed that PyrBTZ01 and BTZ043 had similar half-lives of ∼100 min. The higher maximum concentration (Cmax) observed for PyrBTZ01 (approximately 3,500 ng/ml) versus BTZ043 (1,923 ng/ml) is most likely due to the higher dose used for the former compound and not improved absorption.

PyrBTZ01 is not active in a mouse model of acute TB.Given the encouraging ADME/T and PK data obtained for PyrBTZ01, we performed an in vivo efficacy study using a mouse model of acute TB. Mice were infected by intravenous injection of M. tuberculosis H37Rv and then treated with PyrBTZ01 (50 mg/kg) or isoniazid (25 mg/kg) once daily, by gavage, 5 days/week for 4 weeks. At the end of the experiment, CFU counts in the lungs were determined. While isoniazid and BTZ043 were effective, leading to ∼3.2-log-unit decreases in the numbers of CFU over 4 weeks, compared to the untreated control group, PyrBTZ01 did not provide any protection to the treated mice, and their microbiological and pathological responses were the same as those of the untreated animals.

DISCUSSION

The pyrrole-benzothiazinone family of compounds described here (in particular, PyrBTZ01 and PyrBTZ02) provides new insights into the chemical and pharmacological requirements for DprE1 inhibition in mycobacteria. Of note, these compounds are the first non-nitro-benzothiazinones that demonstrate significant mycobacterial activity in vitro. Several noncovalent DprE1 inhibitors have been described recently (12, 18, 20, 21, 25), and these display MIC values close to those of PyrBTZ01 and PyrBTZ02 presented in this work. In particular, TCA1 (18) and the azaindoles (26) were reported to be efficacious in a mouse model of TB, although those compounds are less potent than BTZ043 or PBTZ169 in vitro (1, 3).

The less favorable MIC values of PyrBTZ01 and PyrBTZ02, compared to their nitro-containing counterparts BTZ043 and PBTZ169, are reflected by considerably higher IC50s against purified M. tuberculosis DprE1 in both its wild-type and BTZ-resistant forms (Table 1). Genetic studies showed that PyrBTZ resistance in M. tuberculosis stemmed from mutations of the active site Cys387 residue, as was reported earlier for the nitro-BTZ counterparts. This was unexpected, since resistant mutants of M. tuberculosis generated against several other noncovalent DprE1 inhibitors, including TCA1 and carboxyquinoxalines, displayed mutations elsewhere, namely, at amino acid residues Gly15, Tyr314, and Leu386 (12, 18, 20). However, molecular docking studies show that PyrBTZ inhibitors occupy roughly the same positions as BTZ043 and PBTZ169 in DprE1, with the pyrrole group being close to and likely clashing with Cys387 (Fig. 4). One possible consequence of this would be the trifluoromethyl group failing to enter the pocket below Cys387 as deeply as the corresponding group on BTZ043 or PBTZ169. This pocket is lined by His132, Gly133, Lys134, Lys367, and Phe369, and the trifluoromethyl moiety forms van der Waals interactions with these residues, as well as forming a hydrogen bond with the amide of Asn385 (21, 27). It is conceivable that the trifluoromethyl group on the pyrrole derivatives fails to make these interactions and this, especially the missing covalent semimercaptal bond, leads to PyrBTZ01 and PyrBTZ02 binding much more weakly to their target than do the nitro-benzothiazinones. This explanation is fully consistent with the respective MICs and IC50s and indicates that the trifluoromethyl moiety is important for stabilizing the interactions between BTZ compounds and DprE1.

PyrBTZ01 and PyrBTZ02 are analogs of BTZ043 and PBTZ169, respectively, that differ solely by replacement of the DprE1-reactive nitro group by a pyrrole. Their in vitro ADME profiles display only minor differences (Table 3), and the in vivo PK profiles of PyrBTZ01, BTZ043, and PBTZ169 in mice are essentially identical (1, 3). Thus, the lack of in vivo efficacy of PyrBTZ01 was not due to insufficient exposure, as satisfactory plasma Cmax and area under the curve values were reached (Fig. 5). The use of similar doses of BTZ043 and PBTZ169 resulted in survival of all treated animals and 1- to 3-log-unit reductions in the bacterial burdens in the lungs in acute and chronic models of TB (1, 3), whereas PyrBTZ01 showed no antituberculosis activity under the same conditions. The combined results suggest that successful inhibition of DprE1 during infection in mammals requires prolonged occupancy of the active site, which may be best achieved by formation of a covalent adduct.

FIG 5
  • Open in new tab
  • Download powerpoint
FIG 5

PK profiles in plasma following oral administration of PyrBTZ01 (50 mg/kg) or BTZ043 (25 mg/kg) to BALB/c mice. Data for BTZ043 in the plot were reported previously (3).

ACKNOWLEDGMENTS

We thank Stefanie Boy-Röttger for technical assistance, Laure Menin for performing mass spectrometry, and Kai Johnsson for fruitful discussions.

The research leading to these results received funding from the European Community Seventh Framework Programme (grant 260872). João Neres was the recipient of a Marie Curie Fellowship from the European Commission (DPRETB project, grant 252802).

FOOTNOTES

    • Received 2 April 2015.
    • Returned for modification 28 April 2015.
    • Accepted 7 May 2015.
    • Accepted manuscript posted online 18 May 2015.
  • ‡ For this virtual institution, see http://www.mm4tb.org.

  • Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.00778-15.

  • Copyright © 2015, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Makarov V,
    2. Manina G,
    3. Mikusova K,
    4. Moellmann U,
    5. Ryabova O,
    6. Saint-Joanis B,
    7. Dhar N,
    8. Pasca MR,
    9. Buroni S,
    10. Lucarelli AP,
    11. Milano A,
    12. De Rossi E,
    13. Belanova M,
    14. Bobovska A,
    15. Dianiskova P,
    16. Kordulakova J,
    17. Sala C,
    18. Fullam E,
    19. Schneider P,
    20. McKinney JD,
    21. Brodin P,
    22. Christophe T,
    23. Waddell S,
    24. Butcher P,
    25. Albrethsen J,
    26. Rosenkrands I,
    27. Brosch R,
    28. Nandi V,
    29. Bharath S,
    30. Gaonkar S,
    31. Shandil RK,
    32. Balasubramanian V,
    33. Balganesh T,
    34. Tyagi S,
    35. Grosset J,
    36. Riccardi G,
    37. Cole ST
    . 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801–804. doi:10.1126/science.1171583.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Mikusova K,
    2. Makarov V,
    3. Neres J
    . 2014. DprE1—from the discovery to the promising tuberculosis drug target. Curr Pharm Des 20:4379–4403. doi:10.2174/138161282027140630122724.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Makarov V,
    2. Lechartier B,
    3. Zhang M,
    4. Neres J,
    5. van der Sar A,
    6. Raadsen S,
    7. Hartkoorn R,
    8. Ryabova O,
    9. Vocat A,
    10. Decosterd L,
    11. Widmer N,
    12. Buclin T,
    13. Bitter W,
    14. Andries K,
    15. Pojer F,
    16. Dyson P,
    17. Cole S
    . 2014. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6:372–383. doi:10.1002/emmm.201303575.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Mikusova K,
    2. Huang HR,
    3. Yagi T,
    4. Holsters M,
    5. Vereecke D,
    6. D'Haeze W,
    7. Scherman MS,
    8. Brennan PJ,
    9. McNeil MR,
    10. Crick DC
    . 2005. Decaprenylphosphoryl arabinofuranose, the donor of the d-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 187:8020–8025. doi:10.1128/JB.187.23.8020-8025.2005.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Christophe T,
    2. Jackson M,
    3. Jeon HK,
    4. Fenistein D,
    5. Contreras-Dominguez M,
    6. Kim J,
    7. Genovesio A,
    8. Carralot J-P,
    9. Ewann F,
    10. Kim EH,
    11. Lee SY,
    12. Kang S,
    13. Seo MJ,
    14. Park EJ,
    15. Skovierova H,
    16. Pham H,
    17. Riccardi G,
    18. Nam JY,
    19. Marsollier L,
    20. Kempf M,
    21. Joly-Guillou ML,
    22. Oh T,
    23. Shin WK,
    24. No Z,
    25. Nehrbass U,
    26. Brosch R,
    27. Cole ST,
    28. Brodin P
    . 2009. High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 5:e1000645. doi:10.1371/journal.ppat.1000645.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Cooper M,
    2. Zuegg J,
    3. Becker B,
    4. Karoli T
    . June 2012. New benzothiazinone compound useful for treating or preventing a microbial infection e.g. tuberculosis or leprosy infection in mammals. WIPO patent WO2012085654-A1.
  7. 7.↵
    1. Gao C,
    2. Ye T-H,
    3. Wang N-Y,
    4. Zeng X-X,
    5. Zhang L-D,
    6. Xiong Y,
    7. You X-Y,
    8. Xia Y,
    9. Xu Y,
    10. Peng C-T,
    11. Zuo W-Q,
    12. Wei Y,
    13. Yu L-T
    . 2013. Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorg Med Chem Lett 23:4919–4922. doi:10.1016/j.bmcl.2013.06.069.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Magnet S,
    2. Hartkoorn RC,
    3. Szekely R,
    4. Pato J,
    5. Triccas JA,
    6. Schneider P,
    7. Szantai-Kis C,
    8. Orfi L,
    9. Chambon M,
    10. Banfi D,
    11. Bueno M,
    12. Turcatti G,
    13. Keri G,
    14. Cole ST
    . 2010. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90:354–360. doi:10.1016/j.tube.2010.09.001.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Tiwari R,
    2. Moellmann U,
    3. Cho S,
    4. Franzblau SG,
    5. Miller PA,
    6. Miller MJ
    . 2014. Design and syntheses of anti-tuberculosis agents inspired by BTZ043 using a scaffold simplification strategy. ACS Med Chem Lett 5:587–591. doi:10.1021/ml500039g.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Karoli T,
    2. Becker B,
    3. Zuegg J,
    4. Moellmann U,
    5. Ramu S,
    6. Huang JX,
    7. Cooper MA
    . 2012. Identification of antitubercular benzothiazinone compounds by ligand-based design. J Med Chem 55:7940–7944. doi:10.1021/jm3008882.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Trefzer C,
    2. Skovierova H,
    3. Buroni S,
    4. Bobovska A,
    5. Nenci S,
    6. Molteni E,
    7. Pojer F,
    8. Pasca MR,
    9. Makarov V,
    10. Cole ST,
    11. Riccardi G,
    12. Mikusova K,
    13. Johnsson K
    . 2012. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1. J Am Chem Soc 134:912–915. doi:10.1021/ja211042r.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Neres J,
    2. Hartkoorn RC,
    3. Chiarelli LR,
    4. Gadupudi R,
    5. Pasca MR,
    6. Mori G,
    7. Venturelli A,
    8. Savina S,
    9. Makarov V,
    10. Kolly GS,
    11. Molteni E,
    12. Binda C,
    13. Dhar N,
    14. Ferrari S,
    15. Brodin P,
    16. Delorme V,
    17. Landry V,
    18. de Jesus Lopes Ribeiro AL,
    19. Farina D,
    20. Saxena P,
    21. Pojer F,
    22. Carta A,
    23. Luciani R,
    24. Porta A,
    25. Zanoni G,
    26. De Rossi E,
    27. Costi MP,
    28. Riccardi G,
    29. Cole ST
    . 2015. 2-Carboxyquinoxalines kill Mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem Biol 10:705–714. doi:10.1021/cb5007163.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Scherman MS,
    2. Kalbe-Bournonville L,
    3. Bush D,
    4. Xin Y,
    5. Deng L,
    6. McNeil M
    . 1996. Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate. J Biol Chem 271:29652–29658. doi:10.1074/jbc.271.47.29652.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Folch J,
    2. Lees M,
    3. Sloane Stanley GH
    . 1957. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497–509.
    OpenUrlFREE Full Text
  15. 15.↵
    1. Sherman W,
    2. Day T,
    3. Jacobson MP,
    4. Friesner RA,
    5. Farid R
    . 2006. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553. doi:10.1021/jm050540c.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Amarnath V,
    2. Valentine WM,
    3. Amarnath K,
    4. Eng MA,
    5. Graham DG
    . 1994. The mechanism of nucleophilic substitution of alkylpyrroles in the presence of oxygen. Chem Res Toxicol 7:56–61. doi:10.1021/tx00037a008.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Zhang M,
    2. Sala C,
    3. Hartkoorn RC,
    4. Dhar N,
    5. Mendoza-Losana A,
    6. Cole ST
    . 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 56:5782–5789. doi:10.1128/AAC.01125-12.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Wang F,
    2. Sambandan D,
    3. Halder R,
    4. Wang J,
    5. Batt SM,
    6. Weinrick B,
    7. Ahmad I,
    8. Yang P,
    9. Zhang Y,
    10. Kim J,
    11. Hassani M,
    12. Huszar S,
    13. Trefzer C,
    14. Ma Z,
    15. Kaneko T,
    16. Mdluli KE,
    17. Franzblau S,
    18. Chatterjee AK,
    19. Johnson K,
    20. Mikusova K,
    21. Besra GS,
    22. Futterer K,
    23. Jacobs WR, Jr,
    24. Schultz PG
    . 2013. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci U S A 110:E2510–E2517. doi:10.1073/pnas.1309171110.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Neres J,
    2. Pojer F,
    3. Molteni E,
    4. Chiarelli LR,
    5. Dhar N,
    6. Boy-Rottger S,
    7. Buroni S,
    8. Fullam E,
    9. Degiacomi G,
    10. Lucarelli AP,
    11. Read RJ,
    12. Zanoni G,
    13. Edmondson DE,
    14. De Rossi E,
    15. Pasca MR,
    16. McKinney JD,
    17. Dyson PJ,
    18. Riccardi G,
    19. Mattevi A,
    20. Cole ST,
    21. Binda C
    . 2012. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4:150ra121. doi:10.1126/scitranslmed.3004395.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Naik M,
    2. Humnabadkar V,
    3. Tantry SJ,
    4. Panda M,
    5. Narayan A,
    6. Guptha S,
    7. Panduga V,
    8. Manjrekar P,
    9. Jena LK,
    10. Koushik K,
    11. Shanbhag G,
    12. Jatheendranath S,
    13. Manjunatha MR,
    14. Gorai G,
    15. Bathula C,
    16. Rudrapatna S,
    17. Achar V,
    18. Sharma S,
    19. Ambady A,
    20. Hegde N,
    21. Mahadevaswamy J,
    22. Kaur P,
    23. Sambandamurthy VK,
    24. Awasthy D,
    25. Narayan C,
    26. Ravishankar S,
    27. Madhavapeddi P,
    28. Reddy J,
    29. Prabhakar K,
    30. Saralaya R,
    31. Chatterji M,
    32. Whiteaker J,
    33. McLaughlin B,
    34. Chiarelli LR,
    35. Riccardi G,
    36. Pasca MR,
    37. Binda C,
    38. Neres J,
    39. Dhar N,
    40. Signorino-Gelo F,
    41. McKinney JD,
    42. Ramachandran V,
    43. Shandil R,
    44. Tommasi R,
    45. Iyer PS,
    46. Narayanan S,
    47. Hosagrahara V,
    48. Kavanagh S,
    49. Dinesh N,
    50. Ghorpade SR
    . 2014. 4-Aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. J Med Chem 57:5419–5434. doi:10.1021/jm5005978.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Panda M,
    2. Ramachandran S,
    3. Ramachandran V,
    4. Shirude PS,
    5. Humnabadkar V,
    6. Nagalapur K,
    7. Sharma S,
    8. Kaur P,
    9. Guptha S,
    10. Narayan A,
    11. Mahadevaswamy J,
    12. Ambady A,
    13. Hegde N,
    14. Rudrapatna SS,
    15. Hosagrahara VP,
    16. Sambandamurthy VK,
    17. Raichurkar A
    . 2014. Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J Med Chem 57:4761–4771. doi:10.1021/jm5002937.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Duan GL,
    2. Smith VH,
    3. Weaver DF
    . 2001. Characterization of aromatic-thiol π-type hydrogen bonding and phenylalanine-cysteine side chain interactions through ab initio calculations and protein database analyses. Mol Phys 99:1689–1699. doi:10.1080/00268970110063917.
    OpenUrlCrossRefWeb of Science
  23. 23.↵
    1. Steiner T,
    2. Koellner G
    . 2001. Hydrogen bonds with π-acceptors in proteins: frequencies and role in stabilizing local 3D structures. J Mol Biol 305:535–557. doi:10.1006/jmbi.2000.4301.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Quillardet P,
    2. Huisman O,
    3. D'Ari R,
    4. Hofnung M
    . 1982. SOS chromotest, a direct assay of induction of an SOS function in Escherichia coli K-12 to measure genotoxicity. Proc Natl Acad Sci U S A 79:5971–5975. doi:10.1073/pnas.79.19.5971.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Shirude PS,
    2. Shandil R,
    3. Sadler C,
    4. Naik M,
    5. Hosagrahara V,
    6. Hameed S,
    7. Shinde V,
    8. Bathula C,
    9. Humnabadkar V,
    10. Kumar N,
    11. Reddy J,
    12. Panduga V,
    13. Sharma S,
    14. Ambady A,
    15. Hegde N,
    16. Whiteaker J,
    17. McLaughlin RE,
    18. Gardner H,
    19. Madhavapeddi P,
    20. Ramachandran V,
    21. Kaur P,
    22. Narayan A,
    23. Guptha S,
    24. Awasthy D,
    25. Narayan C,
    26. Mahadevaswamy J,
    27. Vishwas KG,
    28. Ahuja V,
    29. Srivastava A,
    30. Prabhakar KR,
    31. Bharath S,
    32. Kale R,
    33. Ramaiah M,
    34. Choudhury NR,
    35. Sambandamurthy VK,
    36. Solapure S,
    37. Iyer PS,
    38. Narayanan S,
    39. Chatterji M
    . 2013. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem 56:9701–9708. doi:10.1021/jm401382v.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Shirude PS,
    2. Shandil RK,
    3. Manjunatha MR,
    4. Sadler C,
    5. Panda M,
    6. Panduga V,
    7. Reddy J,
    8. Saralaya R,
    9. Nanduri R,
    10. Ambady A,
    11. Ravishankar S,
    12. Sambandamurthy VK,
    13. Humnabadkar V,
    14. Jena LK,
    15. Suresh RS,
    16. Srivastava A,
    17. Prabhakar KR,
    18. Whiteaker J,
    19. McLaughlin RE,
    20. Sharma S,
    21. Cooper CB,
    22. Mdluli K,
    23. Butler S,
    24. Iyer PS,
    25. Narayanan S,
    26. Chatterji M
    . 2014. Lead optimization of 1,4-azaindoles as antimycobacterial agents. J Med Chem 57:5728–5737. doi:10.1021/jm500571f.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Batt SM,
    2. Jabeen T,
    3. Bhowruth V,
    4. Quill L,
    5. Lund PA,
    6. Eggeling L,
    7. Alderwick LJ,
    8. Fuetterer K,
    9. Besra GS
    . 2012. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci U S A 109:11354–11359. doi:10.1073/pnas.1205735109.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis
Vadim Makarov, João Neres, Ruben C. Hartkoorn, Olga B. Ryabova, Elena Kazakova, Michal Šarkan, Stanislav Huszár, Jérémie Piton, Gaëlle S. Kolly, Anthony Vocat, Trent M. Conroy, Katarína Mikušová, Stewart T. Cole
Antimicrobial Agents and Chemotherapy Jul 2015, 59 (8) 4446-4452; DOI: 10.1128/AAC.00778-15

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis
Vadim Makarov, João Neres, Ruben C. Hartkoorn, Olga B. Ryabova, Elena Kazakova, Michal Šarkan, Stanislav Huszár, Jérémie Piton, Gaëlle S. Kolly, Anthony Vocat, Trent M. Conroy, Katarína Mikušová, Stewart T. Cole
Antimicrobial Agents and Chemotherapy Jul 2015, 59 (8) 4446-4452; DOI: 10.1128/AAC.00778-15
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596